Probiotic agent for adjusting GLP-1 level and application thereof

Abstract

The invention discloses a probiotic agent for adjusting the level of GLP-1 and application of the probiotic agent. The probiotic agent comprises ackermania muciniphila AH39, the ackermania muciniphila AH39 is preserved in the Guangdong Microbiological Culture Collection Center, and the preservation number is GDMCC NO: 65707; the preservation time is January 2, 2025; the inventor finds that the Akkermansia muciniphila AH39 can improve the secretion level of GLP-1 in the intestinal tract, promote the expression of the GLP-1 in the intestinal tract, reduce blood sugar and improve obesity symptoms, and finally the purpose of reducing the weight and blood sugar of obese people is achieved.

Description

Technical Field

[0001] The present invention relates to the field of microbial technology, and in particular to a probiotic agent for regulating GLP-1 levels and application thereof. Background Art

[0002] Obesity refers to a certain degree of obvious overweight and excessive fat layer, which is a state caused by excessive accumulation of body fat, especially triglycerides. Excessive accumulation of body fat due to excessive food intake or changes in body metabolism causes excessive weight gain and causes pathological and physiological changes or lurking in the human body. Assessment criteria: Obesity = (actual weight - standard weight) ÷ standard weight × ± 100%. Weight loss methods include: enema weight loss method, osmotic pressure weight loss method, sauna weight loss method, milk powder weight loss method, rope skipping weight loss method, Pu'er tea weight loss method, etc.

[0003] Intestinal flora, normal microorganisms in the human intestine, such as bifidobacteria and lactobacilli, can synthesize a variety of vitamins necessary for human growth and development, such as B vitamins (vitamins B1, B2, B6, B12), vitamin K, niacin, pantothenic acid, etc., and can also use protein residues to synthesize essential amino acids, such as phenylalanine, valine and threonine, and participate in the metabolism of carbohydrates and proteins. At the same time, it can also promote the absorption of mineral elements such as iron, magnesium and zinc. These nutrients play an important role in human health. Once lacking, they can cause a variety of diseases. There are 10 trillion bacteria parasitic in the human intestine, which can affect body weight and digestion ability, resist the risk of infection and autoimmune diseases, and control the body's response to cancer treatment drugs.

[0004] Glucagon-like peptide-1 (GLP-1) is a hormone mainly produced by intestinal L cells and belongs to the incretin group. Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a new type of hypoglycemic drug in recent years. It activates GLP-1 receptors, enhances insulin secretion in a glucose concentration-dependent manner, inhibits glucagon secretion, and can delay gastric emptying. It reduces food intake through central appetite suppression, thereby achieving the effects of lowering blood sugar and losing weight.

[0005] Therefore, providing a method that can regulate the level of Changdan GLP-1 is of great significance for lowering blood sugar and losing weight. Summary of the invention

[0006] The purpose of the present invention is to provide a probiotic for regulating the level of GLP-1 and its application. The probiotic of the present invention can regulate the secretion level of intestinal GLP-1, thereby achieving the purpose of lowering blood sugar and improving obesity.

[0007] In order to achieve the above-mentioned purpose of the present invention, the following technical solutions are particularly adopted:

[0008] The first aspect of the present invention provides a probiotic for regulating GLP-1 levels, characterized in that the probiotic comprises Akkermansia muciniphila AH39, and the Akkermansia muciniphila AH39 is deposited in Guangdong Microbiological Culture Collection Center with a deposit number of GDMCC NO: 65707; the deposit time is January 2, 2025.

[0009] Preferably, the probiotic is a solid preparation or a liquid preparation.

[0010] Preferably, the content of Akkermansia muciniphila AH39 in the probiotic is not less than 1×10 7 AFU / ml or 1×10 7 AFU / g or 1×10 7 TFU / g or 1×10 7 TFU / ml.

[0011] Preferably, the dosage forms of the probiotics include freeze-dried powder, tablets, capsules, beverages and granules.

[0012] Preferably, the probiotics also include prebiotics and protective agents.

[0013] Preferably, the prebiotic is selected from at least one of inulin, galacto-oligosaccharide, xylo-oligosaccharide, fructo-oligosaccharide and maltodextrin.

[0014] Preferably, the protective agent is selected from at least one of trehalose, gum arabic, lactose and sorbitol.

[0015] The second aspect of the present invention provides a use of the above-mentioned probiotic in the preparation of a product for regulating GLP-1 levels.

[0016] The third aspect of the present invention provides a use of the above-mentioned probiotic in the preparation of a drug for treating or preventing obesity and hyperglycemia.

[0017] Preferably, the drug further comprises a pharmaceutically acceptable excipient.

[0018] Compared with the prior art, the beneficial effects of the present invention include at least:

[0019] The inventors of the present application have discovered that Akkermansia muciniphila AH39 can increase the secretion level of GLP-1 in the intestine, promote the expression of GLP-1 in the intestine, lower blood sugar and improve obesity symptoms, and ultimately achieve the purpose of reducing the weight and blood sugar of obese people. DETAILED DESCRIPTION

[0020] The following embodiments of the technical solution of the present invention are described in detail in conjunction with the embodiments. The following embodiments are only used to more clearly illustrate the technical solution of the present invention, and are therefore only used as examples, and cannot be used to limit the protection scope of the present invention.

[0021] It should be noted that, unless otherwise specified, the technical terms or scientific terms used in this application should have the common meanings understood by those skilled in the art to which the present invention belongs.

[0022] An embodiment of the present invention provides a probiotic for regulating GLP-1 levels, characterized in that the probiotic includes Akkermansia muciniphila AH39, and the Akkermansia muciniphila AH39 is deposited in Guangdong Microbiological Culture Collection Center with a deposit number of GDMCC NO: 65707; the deposit time is January 2, 2025.

[0023] The inventors of the present application have discovered that Akkermansia muciniphila AH39 can increase the secretion level of GLP-1 in the intestine, promote the expression of GLP-1 in the intestine, lower blood sugar and improve obesity symptoms, and ultimately achieve the purpose of reducing the weight and blood sugar of obese people.

[0024] In one embodiment, the probiotic is a solid preparation or a liquid preparation.

[0025] In one embodiment, the content of Akkermansia muciniphila AH39 in the probiotic is not less than 1×10 7 AFU / ml or 1×10 7 AFU / g or 1×10 7 TFU / g or 1×10 7 TFU / ml.

[0026] In one embodiment, the dosage form of the probiotics includes lyophilized powder, tablets, capsules, beverages and granules.

[0027] In one embodiment, the probiotics further include prebiotics and protective agents.

[0028] In one embodiment, the prebiotic is selected from at least one of inulin, galacto-oligosaccharide, xylo-oligosaccharide, fructo-oligosaccharide and maltodextrin.

[0029] In one embodiment, the protective agent is selected from at least one of trehalose, gum arabic, lactose and sorbitol.

[0030] Another embodiment of the present invention provides a use of the above-mentioned probiotic in the preparation of a product for regulating GLP-1 levels.

[0031] Still another embodiment of the present invention provides a use of the above-mentioned probiotic agent in the preparation of a drug for treating or preventing obesity and hyperglycemia.

[0032] In one embodiment, the medicament further comprises a pharmaceutically acceptable excipient.

[0033] The technical solution of the present invention is further described in detail below through specific embodiments.

[0034] Example

[0035] This example is the screening of Akkermansia muciniphila AH39:

[0036] Two samples of feces from healthy women were selected, and after gradient dilution, they were applied to LBS medium supplemented with 1% mycotoxin and cultured in an anaerobic incubator for enrichment for 60 hours. After culture, colonies were picked up with an inoculation loop for streaking and purification, and 13 strains were obtained.

[0037] The 13 obtained strains were inoculated into BHI liquid culture medium for expansion culture at a temperature of 37 degrees Celsius for 72 hours; then, the expanded culture strains were counted;

[0038] STC-1 cells were inoculated into 48-well plates. When the cells grew to 80% confluence, 10% of the volume of different strains (1×10 9 AFU / ml) were cultured in a 37°C incubator for 1 h;

[0039] Then, the culture medium was collected and centrifuged at 1200 r / min for 10 min at 4 °C, and the supernatant was collected. This was repeated three times;

[0040] The concentration of GLP-1 in the supernatant was determined by ELISA, and the test results are shown in Table 1 ;

[0041] Table 1

[0042]

[0043]

[0044] From Table 1, we can see that:

[0045] The fifth group of bacteria can better promote the secretion of GLP-1. They were identified as Akkermansia muciniphila and named as Akkermansia muciniphila AH39. Their morphological identification characteristics are as follows: oval colonies with grayish white color.

[0046] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention, and they should all be included in the scope of the claims and specification of the present invention.

Claims

1. A probiotic for regulating GLP-1 levels, characterized in that: The probiotic includes Akkermansia muciniphila AH39, which is deposited in Guangdong Microbiological Culture Collection Center with a deposit number of GDMCC NO: 65707 and a deposit time of January 2, 2025.

2. The probiotic according to claim 1, characterized in that The probiotic is a solid preparation or a liquid preparation.

3. The probiotic according to claim 2, characterized in that The content of Akkermansia muciniphila AH39 in the probiotic is not less than 1×10 7 AFU / ml or 1×10 7 AFU / g or 1×10 7 TFU / g or 1×10 7 TFU / ml.

4. The probiotic according to claim 1, characterized in that The dosage forms of the probiotics include freeze-dried powder, tablets, capsules, beverages and granules.

5. The probiotic according to claim 1, characterized in that The probiotics also include prebiotics and protective agents.

6. The probiotic according to claim 5, characterized in that The prebiotic is selected from at least one of inulin, galacto-oligosaccharide, xylo-oligosaccharide, fructo-oligosaccharide and maltodextrin.

7. The probiotic according to claim 5, characterized in that The protective agent is selected from at least one of trehalose, gum arabic, lactose and sorbitol.

8. Use of the probiotic according to any one of claims 1 to 7 in the preparation of a product for regulating GLP-1 levels.

9. Use of the probiotic according to any one of claims 1 to 7 in the preparation of a drug for treating or preventing obesity and hyperglycemia.

10. The use according to claim 9, characterized in that: The drug also includes pharmaceutically acceptable excipients.

Images